Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

that is very common. What that means is

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Black-Ops Member Profile
 
Followed By 126
Posts 2,222
Boards Moderated 0
Alias Born 06/21/18
160x600 placeholder
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 11/30/2021 6:32:42 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 11/30/2021 6:32:41 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 11/30/2021 6:31:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/29/2021 6:30:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/29/2021 6:27:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/29/2021 6:20:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/24/2021 5:22:56 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/24/2021 4:05:01 PM
CytoDyn reports leronlimab data in NASH trial for first 15 patients Seeking Alpha - 11/24/2021 10:08:44 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/23/2021 5:24:15 PM
SA Breaking News - PURA estimates $1M in 2022 revenue InvestorsHub NewsWire - 11/22/2021 9:38:18 AM
PURA BULLISH RESURGANCE InvestorsHub NewsWire - 11/19/2021 8:50:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/17/2021 6:02:41 AM
CytoDyn submits the first section of HIV BLA to FDA under rolling review Seeking Alpha - 11/16/2021 7:07:29 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/9/2021 4:55:20 PM
CytoDyn submits leronlimab Breakthrough Therapy designation application to the FDA Seeking Alpha - 11/8/2021 7:50:43 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/5/2021 11:30:49 AM
CytoDyn posts preliminary results from mid-stage leronlimab NASH study Seeking Alpha - 11/3/2021 6:11:13 AM
iQSTEL, Inc. - The Calm Before The Surge (OTCQX: IQST) InvestorsHub NewsWire - 10/29/2021 2:31:48 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/28/2021 2:06:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/28/2021 1:58:46 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/27/2021 4:27:55 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/21/2021 4:10:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/21/2021 4:07:39 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/20/2021 5:28:12 PM
Black-Ops   Thursday, 11/25/21 07:38:09 PM
Re: 3X Charm post# 194796
Post # of 196172 
that is very common. What that means is that the Warts and common are seperate. Two securities. A Wart holder can exercise today, tomorrow, anytime. BUT IT DOES NOT MEAN THAT THE WART HOLDER CAN SELL.

The Warts, once exercised must be fully paid andthen become common. After six months and one day the former wart holder and now a holder of additional common can sell the Wart sourced common.

I trust my describtion of how such securities are negotiated / sold is complete.

Example. Joe Verybright bought 100,000$ CYDY common at 1$ in the Private Placement. With that common was 30% Wart coverage or in other words 30,000 warts.

lets say the common was fully paid for by wired funds on 11/22/2021

The warts are still there. Their 6 month run does not start until they are exercised; hence they become fully paid for common.

Lets say the Warts are exercised on 12/24/2021

On May 23rd, 2022 the common can be sold under SEC rules.

On June 25th, 2022 the common sourced via the warts can be sold.

Now all CYDY shareholders know the true facts.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences